Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigation of the effect of the various complement geneotype and phenotype in the outcome of ranibizumab treatment in patients of age related mascular degeneration (AMD).

Next Previous
Search
Trial Profile

An investigation of the effect of the various complement geneotype and phenotype in the outcome of ranibizumab treatment in patients of age related mascular degeneration (AMD).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Dec 2015 Status changed from completed to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 12 Nov 2015 Status changed from recruiting to completed, as reported by United Kingdom Clinical Research Network record.
    • 04 Sep 2015 Accrual to date is 77% as reported by United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top